Welcome to the Wnt & β-Catenin Targeted Drug Development Summit
Turning Biology into Translational Insights to Support Clinical Development of Wnt/β-Catenin Candidates to Offer a Safe, Efficacious First-in-Class IO Therapy for Patients
With an improved understanding of biology and mechanisms of action, the Wnt/β-Catenin community is surging through clinic in 2022 with positive clinical updates. The excitement of a potential first-in-class candidate to advent combination, immuno-oncology therapies in colorectal, head & neck and non-small cell lung cancer is offering hope for patients with high unmet medical needs.
After 2 decades of research, we are excited to see milestones reached within drug developers, including Tonix Pharmaceuticals targeting Wnt/ β-catenin pathway as a broad-spectrum antiviral strategy, Boehringer Ingelheim/Surrozen collaboration seeking retinal therapies along the Wnt pathway. It is now the time for drug developers to act and get together at the 2nd Wnt/β-Catenin Pathway Targeted Drug Development Summit. As the one and only industry-led meeting, you will be equipped with unparalleled insights in:
- Wnt/β-Catenin’s structural biology and medicinal chemistry – turning the undruggable druggable
- Comparison of different Wnt/β-Catenin modulation approaches, its interaction with TIL and tumor microenvironment for targeted, combination therapies
- Translating basic science into clinical design – from scheduling to dosing, overcoming toxicity to widen the therapeutic window with safety in mind
- Validating a clinical biomarker for patient selection
In collaboration with Wnt/β-Catenin pioneers such as Iterion Therapeutics, Leap Therapeutics, FogPharma, this is your unique opportunity to join and meet 60+ drug developers to forge long-term collaboration and advance Wnt/β-Catenin as a valuable target and clinical asset, propelling to provide first-in-class treatments for patients!
What can you expect to learn this year?
Accelerate your Pipeline - Assess
the therapeutic potential of this
pathway across oncology by hearing from Acworth Pharma and Beatston Institute to build the latest knowledge into your R&D strategy
Overcome Safety Concerns - Understanding what you can do within safety and scheduling, to reduce toxicity alongside short and long term impacts for clinical success with Iterion Therapeutics
Novel Approaches - Examine novel
approaches in the Wnt pathway from Pfizer, Boston School of Medicine, and Pin Therapeutics, and dive into new modulation approaches and combination therapies
Translational Insights - Learn about the newest preclinical advancements from MD Anderson and Fog Pharma, understand where cutting-edge development will take us into 2023
Clinical Progress - Hear updates from the most recent clinical trials with Leap Therapeutics, Redx Pharma and Ohio State University deep-diving into their most recent results